Related Experiment Video
Updated: Jan 28, 2026

Automation of Mode Locking in a Nonlinear Polarization Rotation Fiber Laser through Output Polarization Measurements
Published on: February 28, 2016
Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP
Nandita Anand1, Michael P Blair2, Mark J Greenwald1
1University of Chicago, Department of Ophthalmology and Visual Science, Chicago, Illinois.
Insights
Intravitreal bevacizumab (IVB) with delayed laser (IVB-PRP) resulted in significantly less myopia in infants with retinopathy of prematurity (ROP) compared to primary laser treatment. This refractive benefit was maintained even with delayed laser application.
Area of Science:
- Ophthalmology
- Neonatology
- Retinal Diseases
Background:
- Retinopathy of prematurity (ROP) is a leading cause of childhood blindness.
- Posterior type 1 ROP requires prompt treatment to prevent severe visual impairment.
- Current treatment options include laser photocoagulation and anti-VEGF therapy.
Purpose of the Study:
- To compare refractive outcomes between primary peripheral retinal photocoagulation (PRP) and intravitreal bevacizumab (IVB) with delayed PRP in infants with posterior type 1 ROP.
- To evaluate the long-term refractive status (spherical equivalent) of treated infants.
Main Methods:
- Retrospective review of 87 infants treated for posterior type 1 ROP between 2006 and 2016.
- Comparison of primary PRP group with IVB-PRP group (IVB supplemented with prophylactic laser).
- Cycloplegic refraction measured between 2 and 4 years of age.
Main Results:
- The IVB-PRP group showed significantly less myopia (mean SE -0.16 D) compared to the primary PRP group (mean SE -7.4 D).
- This difference remained significant across different ROP zones and severity.
- No significant difference in refractive outcomes was observed between IVB-PRP and IVB monotherapy.
Conclusions:
- Intravitreal bevacizumab with delayed laser photocoagulation leads to better refractive outcomes in infants with posterior type 1 ROP.
- Delayed laser treatment did not diminish the refractive advantages of initial IVB therapy.
- IVB-PRP represents a promising alternative for managing posterior type 1 ROP with reduced myopia.
Purpose:
To compare the refractive outcomes of intravitreal bevacizumab (IVB) and delayed peripheral retinal photocoagulation (PRP) with primary PRP in infants treated for posterior type 1 ROP.
Methods:
The medical records of 87 infants at a tertiary referral center treated for posterior type 1 ROP between 2006 and 2016 were reviewed retrospectively. Consecutive infants received primary PRP before and primary IVB after a change in treatment practice implemented in early 2011. In most cases primary IVB was supplemented with prophylactic laser treatment after 60 weeks' PMA (IVB-PRP). The main outcome was spherical equivalent (SE) in diopters, determined by cycloplegic refraction between 2 and 4 years. Infants treated with IVB-PRP were also compared to the those who received only IVB as monotherapy.
Results:
The final analysis included 34 eyes of 19 infants in the primary PRP group and 40 eyes of 21 infants in the IVB-PRP group. Mean SE was -7.4 ± 5.2 D in the primary PRP group and -0.16 ± 2.2 D in the IVB-PRP group (P < 0.001). This relationship persisted after stratification by zone of ROP and the presence of aggressive posterior ROP. There was no statistically significant difference in mean SE between the IVB-PRP group and the 8 eyes of 4 infants who received IVB as monotherapy. Of 46 infants who received primary IVB, 37 completed an examination under anesthesia after 60 weeks' PMA. In these patients, 70% of eyes showed peripheral vascular leakage on fluorescein angiography.
Conclusions:
In our study cohort, infants treated with IVB-PRP were significantly less myopic than those treated with primary PRP. Delayed laser after 60 weeks' PMA, in hopes of reducing the risk of late reactivation with retinal detachment, did not negate the refractive benefits of primary IVB.
Related Concept Videos
Primary Active Transport
Primary Active Transport
Primary and Secondary Growth in Roots and Shoots
Primary Production
Primary Distribution
Nomenclature of Primary Amines

